Sun Pharma Acquires Organon in $10B Transaction

Sun Pharmaceutical Industries has signed a definitive agreement to acquire all outstanding shares of Organon for $11.75 billion in an all-cash deal, underscoring its strategic push into expanding its portfolio in women’s health and biosimilars. The acquisition values Organon's shares at $14 each. This agreement is set to establish Sun Pharma as a more significant player in the global pharmaceutical industry, with enhanced capabilities in established brands, branded generics, and the growing biosimilars market.

Organon, a New Jersey-based global healthcare company, was formed as a spinoff from Merck. It specializes in women’s health and general medicine, boasting over 70 products in its portfolio. The company operates in 140 countries, with significant markets across the U.S., Europe, China, Canada, and Brazil. Organon's infrastructure includes six manufacturing facilities in the European Union and emerging markets. The company reported revenues of $6.2 billion and an adjusted EBITDA of $1.9 billion for the fiscal year ending December 2025, while holding $8.6 billion in debt and a cash balance of $574 million.

The acquisition aligns with Sun Pharma’s strategy to enhance its Innovative Medicines business, integrating Organon's diverse offerings and robust global presence under its umbrella. Sun Pharma anticipates that the deal will make it one of the top three companies in women's health on a global scale, and it aims to become the largest player in biosimilars worldwide. Additionally, the acquisition is expected to double Sun Pharma's EBITDA and cash flow, aiding in debt reduction post-transaction.

Within the sector, this move signals intensified competition among pharmaceutical giants, particularly in women’s health and biosimilars—markets projected to experience significant growth. Sun Pharma's expansion could apply pressure on competitors to pursue similar strategic moves or collaborations to maintain their market positions. The deal also suggests a broader industry trend towards consolidation as firms seek scale and diversification.

The transaction, which has received unanimous approval from the boards of both companies, requires the nod from Organon stockholders and regulatory authorities. Sun Pharma intends to finance the acquisition using available cash and committed financing from banks. The merger, where Organon will survive as a subsidiary, is expected to close in early 2027, pending fulfillment of standard closing conditions.